US Drug Recall Register

FDA Drug Recalls

14,801 recalls, newest first

Class II · Moderate risk Terminated

Deferoxamine 4 grams/NS 101 mL Cassette

Reason Lack of Sterility Assurance

Baptist Health Medical Towers Pharmacy and Infusion Services D-0923-2016
Class II · Moderate risk Terminated

Deferoxamine 2 grams/51 mL NS cassette

Reason Lack of Sterility Assurance.

Baptist Health Medical Towers Pharmacy and Infusion Services D-0922-2016
Class II · Moderate risk Terminated

Daptomycin 650 mg in 50 mL 0.9% NS bag

Reason Lack of Sterility Assurance

Baptist Health Medical Towers Pharmacy and Infusion Services D-0921-2016
Class II · Moderate risk Terminated

D5 1/2 NS 1000 mL with Electrolytes bag

Reason Lack of Sterility Assurance

Baptist Health Medical Towers Pharmacy and Infusion Services D-0920-2016
Class II · Moderate risk Terminated

Clindamycin 900 mg in 100 mL 0.9% NS bag

Reason Lack of Sterility Assurance

Baptist Health Medical Towers Pharmacy and Infusion Services D-0919-2016
Class II · Moderate risk Terminated

Cefazolin 6 grams in 292 mL 0.9% NS bags

Reason Lack of Sterility Assurance

Baptist Health Medical Towers Pharmacy and Infusion Services D-0915-2016
Class II · Moderate risk Terminated

Ascorbic Acid 500 mg

Reason Lack of Sterility Assurance

Baptist Health Medical Towers Pharmacy and Infusion Services D-0914-2016
Class II · Moderate risk Terminated

70% Ethanol-lock Solution

Reason Lack of Sterility Assurance

Baptist Health Medical Towers Pharmacy and Infusion Services D-0913-2016
Class II · Moderate risk Terminated

Oxycodone Hydrochloride Oral Solution

Reason Defective Container: Excess lidding material accumulation between the seal and the cup resulting in the lid not properly adhering and allowing leakage.

VistaPharm, Inc. NDC 66689-401-01 D-0838-2016
Class II · Moderate risk Terminated

Brevibloc DOUBLE STRENGTH Premixed Injection

Reason Discoloration: presence of atypical yellow discoloration of the solution .

Baxter Healthcare Corp. NDC 10019-075-87 D-0852-2016
Class III · Low risk Terminated

SKY Aspirin Chewable Tablets

Reason Labeling: Label mix-up -outer carton incorrectly labeled as aspirin chewable tablets.

Mckesson Packaging Services NDC 63739-434-01 D-0834-2016
Class III · Low risk Terminated

BuPROPion Hydrochloride Extended-release Tablets

Reason Failed Impurities/Degradation Specifications: high out of specification results for one of the known degradation products, m-chlorobenzoic acid.

Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-317-60 D-0671-2017
Class III · Low risk Terminated

BuPROPion Hydrochloride Extended-release Tablets

Reason Failed Impurities/Degradation Specifications: high out of specification results for one of the known degradation products, m-chlorobenzoic acid.

Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-316-60 D-0670-2017
Class III · Low risk Terminated

BuPROPion Hydrochloride Extended-release Tablets

Reason Failed Impurities/Degradation Specifications: high out of specification results for one of the known degradation products, m-chlorobenzoic acid.

Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-315-60 D-0669-2017
Class III · Low risk Terminated

Haloperidol Decanoate Injection

Reason Failed Impurities/Degradation Specifications: Firm is recalling product due to an impurity out-of-specification result.

Fresenius Kabi USA, LLC NDC 63323-469-01 D-0818-2016
Class III · Low risk Terminated

Lisinopril Tablets USP

Reason CGMP Deviations: finished products manufactured using active pharmaceutical ingredients whose intermediates failed specifications.

Lupin Pharmaceuticals Inc. NDC 68180-517-03 D-1503-2016
Class III · Low risk Terminated

Lisinopril Tablets USP

Reason CGMP Deviations: finished products manufactured using active pharmaceutical ingredients whose intermediates failed specifications.

Lupin Pharmaceuticals Inc. NDC 68180-516-02 D-1502-2016
Class II · Moderate risk Terminated

Cisatracurium Besylate Injection

Reason Incorrect/ Undeclared Excipient: Firm is recalling product due to an incorrect statement of Preservative free on the individual carton label. The vial label and outer carton label contain the correct statement of 0.9% benzyl alcohol added as a preservative.

Fresenius Kabi USA, LLC NDC 63323-417-10 D-0819-2016